Related Experiment Video
Updated: Oct 5, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
Rational Immunogenicity Modulation of Virus-Like Particles by VLPIM
Chufan Wang1, Yeyun Chen2,3, Ming-Wei Wang1,4,5,6,7
1Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Abstract:
Virus-like particles (VLPs) are versatile platforms for drug delivery and vaccine development, but precisely customizing their immune profiles for specific clinical applications remains challenging. Here, we present a computational framework that integrates complementary artificial-intelligence-driven tools for protein design, structure prediction, and antigenicity assessment to enable rational immunogenicity modulation of VLPs while preserving their structural integrity. Leveraging the central role of CD4+ T cells in adaptive immunity, this framework first combines class II major histocompatibility complex (MHC-II)-restricted epitope prediction with structure-guided sequence optimization to generate a focused mutation library. Subsequently, its virtual screening workflow combines immunogenicity predictions and structural modeling to pinpoint variants likely to attenuate or enhance CD4+ T cell activation while preserving VLP integrity. This framework enables a broader and more efficient exploration of the mutation space to identify VLP structural variants with tailored immunogenicity profiles; hence, we term it the VLPIM (Virus-Like Particle Immunogenicity Modulation) platform. Using hepatitis B core VLPs as proof of concept, VLPIM generated a mutation library of 120 variants, computationally filtered down to 4 candidates, and ultimately identified 2 variants that retained native virus-like morphology, as confirmed by transmission electron microscopy. In vitro immunogenicity assays confirmed that epitope substitutions could either suppress or enhance CD4+ T cell activation. This generalizable pipeline permits precise immunogenicity modulation of VLPs and other multimers, accelerating their development as targeted drug carriers and next-generation vaccine platforms. VLPIM is available as both a locally executable tool on GitHub (https://github.com/RuijinHospitalVNAR/VLPIM) and an online web server (https://ruijinhospitalvnar.github.io/Toolboxes/VLPIM_Web_services/).
Related Concept Videos
Vaccines
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Respiratory Syncytial Virus Disease
Vaccinations
Inhibitors of Viral Protein Synthesis

